Results 151 to 160 of about 240,836 (199)
Some of the next articles are maybe not open access.
pharma-kritik, 2021
Andexanet alfa: Mit Andexanet alfa (Ondexxya®) steht ein Medikament zur Verfügung, mit dem die antikoagulierende Wirkung von Faktor-Xa-Hemmern wie z.B. Rivaroxaban (Xarelto®) aufgehoben werden kann. Ob es bei bedrohlichen Blutungen besser wirkt als eine Therapie mit Prothrombinkomplex-Konzentraten, ist noch nicht ...
openaire +1 more source
Andexanet alfa: Mit Andexanet alfa (Ondexxya®) steht ein Medikament zur Verfügung, mit dem die antikoagulierende Wirkung von Faktor-Xa-Hemmern wie z.B. Rivaroxaban (Xarelto®) aufgehoben werden kann. Ob es bei bedrohlichen Blutungen besser wirkt als eine Therapie mit Prothrombinkomplex-Konzentraten, ist noch nicht ...
openaire +1 more source
Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Efficacy and safety of andexanet alfa for factor Xa inhibitor-associated intracranial haemorrhage
Journal of Neurology Neurosurgery & PsychiatryBackground Current international guidelines suggest andexanet alfa (AA) for the management of factor Xa inhibitor-associated intracranial haemorrhage (ICH).
G. Tsivgoulis +12 more
semanticscholar +1 more source
Andexanet Alfa (Andexxa) Formulary Review
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2019Andexanet alfa, a recombinant modified human “decoy” factor Xa (FXa) protein, is the first and only available antidote approved by the Food and Drug Administration to manage life-threatening or uncontrolled bleeding associated with the anti-Xa agents.
Nahal, Beik +6 more
openaire +2 more sources
Clinical neurology and neurosurgery (Dutch-Flemish ed. Print)
INTRODUCTION In 2018, andexanet alfa (Andexxa) became FDA approved as an anti-factor Xa inhibitor reversal agent for patients who require the reversal of anticoagulation due to rivaroxaban (Xarelto) or apixaban (Eliquis).
Asha Sethuraman +12 more
semanticscholar +1 more source
INTRODUCTION In 2018, andexanet alfa (Andexxa) became FDA approved as an anti-factor Xa inhibitor reversal agent for patients who require the reversal of anticoagulation due to rivaroxaban (Xarelto) or apixaban (Eliquis).
Asha Sethuraman +12 more
semanticscholar +1 more source
Andexanet Alfa for Reversing Factor Xa Inhibition
Cardiology in Review, 2019The direct oral anticoagulants (DOACs) have gained popularity recently among both patients and providers for their comparable or better efficacy and safety profiles compared with warfarin and the lack of need for routine monitoring of anticoagulant effect. One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a
Alexandra M, Sible, James J, Nawarskas
openaire +2 more sources
In Brief: Andexanet alfa (Andexxa) Withdrawn
The Medical Letter on Drugs and TherapeuticsAndexanet alfa (Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto), has voluntarily been withdrawn from the market.1 Andexxa was the only drug FDA-approved for this indication in the US.
openaire +2 more sources